Idiopathic Pulmonary Fibrosis - 25 Studies Found

RECRUITING : To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
: Idiopathic Pulmonary Fibrosis
: 2024-11-21
: BBT-877 24 weeks + Follow-up 4 weeks
COMPLETED : Dose Reduction and Discontinuation With Anti-Fibrotic Medications
: Idiopathic Pulmonary Fibrosis
: 2024-11-21
: Pirfenidone
COMPLETED : Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients
: Idiopathic Pulmonary Fibrosis
: 2024-11-21
: Nintedanib
RECRUITING : A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients
: Idiopathic Pulmonary Fibrosis
: 2024-11-21
: Caveolin-1-Scaffolding-Protein-Derived Peptide
RECRUITING : Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
: Idiopathic Pulmonary Fibrosis
: 2024-11-21
: PLN-74809
RECRUITING : Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
: Idiopathic Pulmonary Fibrosis
: 2024-11-21
: Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity).300 mg EGCG (2 capsules) taken orally daily for 12 weeks.Dru
RECRUITING : Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
: Idiopathic Pulmonary Fibrosis
: 2024-11-21
: Orally via a tablet.
RECRUITING : A Study to Investigate Leramistat in Patients With IPF
: Idiopathic Pulmonary Fibrosis
: 2024-11-21
: Drug: Leramistat
RECRUITING : A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
: Idiopathic Pulmonary Fibrosis
: 2024-11-21
: Vixarelimab will be administered as per the schedule specified in the respective arms.
COMPLETED : Neuromuscular Electrical Stimulation in Patients With Idiopathic Pulmonary Fibrosis
: Idiopathic Pulmonary Fibrosis
: 2024-11-21
: A 20-30 minutes low-medium intensity aerobic exercise training with cycling ergometer.
<<< Previous | Next >>>